Anti-PLA2R1 Antibodies and Kidney Transplant Recurrence
Author Information
Author(s): Cremoni Marion, Teisseyre Maxime, Thaunat Olivier, Fernandez Céline, Payre Christine, Moutou Alan, Zarif Hadi, Brglez Vesna, Albano Laetitia, Moal Valérie, Mourad Georges, Morelon Emmanuel, Hurault de Ligny Bruno, Zaoui Philippe, Rondeau Eric, Ouali Nacera, Ronco Pierre, Moulin Bruno, Braun-Parvez Laura, Durrbach Antoine, Heng Anne-Elisabeth, Grimbert Philippe, Ducloux Didier, Blancho Gilles, Merville Pierre, Choukroun Gabriel, Le Meur Yannick, Vigneau Cécile, Mariat Christophe, Rostaing Lionel, Subra Jean-François, Taupin Jean-Luc, Lambeau Gérard, Esnault Vincent, Sicard Antoine, Seitz-Polski Barbara
Primary Institution: Centre de Référence Maladies Rares Syndrome Néphrotique Idiopathique, Centre Hospitier Universitaire de Nice, Nice, France
Hypothesis
The presence of pretransplant anti-PLA2R1 antibodies predicts the recurrence of membranous nephropathy after kidney transplantation.
Conclusion
Pretransplant anti-PLA2R1 antibodies are a strong predictor of membranous nephropathy recurrence after kidney transplantation.
Supporting Evidence
- Patients with anti-PLA2R1 antibodies had a 54% recurrence rate compared to 9% in those without.
- The study included 178 patients, with 137 analyzed after exclusions.
- Monitoring anti-PLA2R1 antibodies post-transplant showed limited value for early recurrence.
- Recurrence occurred rapidly, with a median delay of 5 months after transplantation.
- Patients with recurrence had significantly higher pretransplant anti-PLA2R1 antibody levels.
- Two cohorts were analyzed: one prospective and one retrospective.
- Patients with high pretransplant antibody levels had a higher risk of allograft loss.
- Statistical analyses confirmed the significance of the findings.
Takeaway
If patients have certain antibodies before getting a kidney transplant, they are more likely to have problems with their new kidney later on.
Methodology
A prospective multicenter study involving 72 patients and a retrospective cohort of 65 patients was conducted to evaluate the impact of anti-PLA2R1 antibodies on nephropathy recurrence.
Potential Biases
Potential bias due to the retrospective nature of part of the study and the exclusion of patients without pretransplant serum.
Limitations
The study did not have complete clinical data on allograft loss causes and lacked a consensus definition of recurrence.
Participant Demographics
The cohort included 137 patients, predominantly male (80%), with a mean age of 55 years.
Statistical Information
P-Value
<0.0001
Confidence Interval
95% CI: 2.3–15.7
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website